Q1 2023 13F Holders as of 3/31/2023
-
Type / Class
-
Debt / NOTE 1.250% 5/1
-
Number of holders
-
44
-
Total 13F principal, excl. options
-
333M
-
Principal change
-
+75.3M
-
Total reported value, excl. options
-
$347M
-
Value change
-
+$77.6M
-
Number of buys
-
22
-
Number of sells
-
-17
-
Price
-
$1.04
Significant Holders of BIOMARIN PHARMACEUTICAL INC - NOTE 1.250% 5/1 as of Q1 2023
55 filings reported holding 09061GAK7 - BIOMARIN PHARMACEUTICAL INC - NOTE 1.250% 5/1 as of Q1 2023.
BIOMARIN PHARMACEUTICAL INC - NOTE 1.250% 5/1 has 44 institutional bondholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of $333M of principal
.
Largest 10 bondholders include Voya Investment Management LLC ($83.6M of principal), MACKAY SHIELDS LLC ($76.4M of principal), LAZARD ASSET MANAGEMENT LLC ($51.2M of principal), Wellesley Asset Management ($32.4M of principal), ADVENT CAPITAL MANAGEMENT /DE/ ($25.2M of principal), Thrivent Financial for Lutherans ($16.3M of principal), Lombard Odier Asset Management (Europe) Ltd ($15.6M of principal), DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main ($14.5M of principal), STATE STREET CORP ($12.2M of principal), and Invesco Ltd. ($8.8M of principal).
This table shows the top 44 institutional bondholders of the company debt. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.